retatrutide phase 2 trial duration weight loss A waterfall graph from the with showing the Lilly's retatrutide shows 28% weight

The TRANSCEND-CKD trial is investigating whether retatrutides anti-inflammatory and weight-reducing effects translate to preserved kidney function in patients with CKD stage G3

Addressing these factors directly from the home allows concierge doctors to develop personalized treatment plans that consider each patients unique needs

Reported side effects are rare and typically mild: mild redness or irritation at the application site (usually resolves with continued use or concentration adjustment), occasional skin tingling at higher concentrations (typically benign), and temporary dryness during initial use

From preparing the site to the injection itself, we cover the essential details to help you feel empowered in managing your health journey.

Phase 3 TRIUMPH trials The most recent data comes from the phase 3 program